Drugs / Lopinavir/ritonavir
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01818258 Comparator | Oct 2015 → Apr 2017 | HIV infectious disease, protein-energy malnutrition | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/ritonavir | “Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks” NCT01818258 ↗ |
| Known as | LPV/r | “Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks” NCT01818258 ↗ |
| Route | Oral | “80/20 mg/ml oral solution administered twice daily” NCT01818258 ↗ |